Ibaraki, Japan

Takao Nakamura


Average Co-Inventor Count = 5.1

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2004-2011

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Takao Nakamura: Innovator in G Protein-Coupled Receptor Research

Introduction

Takao Nakamura is a prominent inventor based in Ibaraki, Japan. He has made significant contributions to the field of biochemistry, particularly in the study of G protein-coupled receptors (GPCRs). With a total of 6 patents, his work has paved the way for advancements in pharmaceutical research and development.

Latest Patents

Nakamura's latest patents include groundbreaking research on the guanosine triphosphate (GTP)-binding protein-coupled receptor protein known as BG37. The present inventors conducted a similarity search of the amino acid sequence of known G protein-coupled receptor proteins in GenBank, leading to the discovery of a novel human GPCR gene named 'BG37'. The cDNA containing the open reading frame (ORF) of the gene was cloned, and its nucleotide sequence was determined. Additionally, novel GPCR 'BG37' genes from mouse and rat were isolated. The use of this novel GPCR enables the screening of ligands, compounds that inhibit binding to a ligand, and candidate pharmaceutical compounds that can regulate signal transduction from the "BG37" receptor.

Career Highlights

Throughout his career, Takao Nakamura has worked with notable companies such as Banyu Pharmaceutical Co. Ltd and Merck Sharp & Dohme Corporation. His expertise in GPCR research has made him a valuable asset in the pharmaceutical industry.

Collaborations

Nakamura has collaborated with esteemed colleagues, including Ken-ichi Tanaka and Hiraku Itadani. Their combined efforts have contributed to the advancement of GPCR research and its applications in medicine.

Conclusion

Takao Nakamura's innovative work in the field of G protein-coupled receptors has led to significant advancements in pharmaceutical research. His contributions continue to influence the development of new therapeutic compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…